Medulloblastoma is a highly malignant primary brain tumor that arises in the cerebellum and is most frequently diagnosed in children, although it can also occur in adults. This tumor develops from primitive neuroectodermal cells and has a strong tendency to spread through cerebrospinal fluid pathways within the central nervous system. The biological mechanisms, diagnostic advances, and therapeutic strategies for this disease are frequently explored at international research forums such as a Cancer Conference, where experts present new findings related to molecular classification and treatment of pediatric brain tumors.

Medulloblastoma originates in the cerebellum, the region of the brain responsible for balance, coordination, and fine motor control. Because of its location, early symptoms often involve neurological changes such as headaches, nausea, vomiting, and difficulty maintaining balance. As the tumor grows, it may obstruct the flow of cerebrospinal fluid, leading to increased intracranial pressure. Researchers have discovered that medulloblastoma is not a single disease but rather a group of molecularly distinct subtypes with different genetic drivers, biological behaviors, and clinical outcomes. Understanding these molecular differences has significantly improved risk stratification and treatment planning.

Advances in genomic research have identified several key molecular subgroups of medulloblastoma, including WNT-activated, SHH-activated, and other genetically defined categories. Each subgroup demonstrates unique patterns of gene expression and tumor biology. These discoveries have helped clinicians predict disease prognosis more accurately and select therapies tailored to specific tumor characteristics. Molecular profiling is therefore becoming a standard component of diagnosis, enabling clinicians to better understand tumor behavior and guide personalized treatment strategies for affected patients.

Treatment for medulloblastoma typically involves a combination of surgery, radiation therapy, and chemotherapy. Surgical removal of the tumor is usually the first step, aiming to reduce tumor burden and relieve pressure within the brain. Radiation therapy is often applied to the brain and spinal cord to eliminate remaining cancer cells that may have spread through cerebrospinal fluid pathways. Chemotherapy may also be used to destroy microscopic disease and reduce recurrence risk. Ongoing research continues to explore targeted therapies and less toxic treatment approaches that may improve survival while minimizing long-term neurological effects for patients diagnosed with medulloblastoma.